A mother's worst nightmare: when her own child becomes a patient. Jenn Janosko, a pediatric nurse, found herself in this unimaginable situation when her four-year-old daughter, Izzy, was diagnosed with a rare and deadly brain cancer called diffuse intrinsic pontine glioma (DIPG). But here's where the story takes a controversial turn: the Trump administration's policies are threatening the very research that could save children like Izzy.
For seven years, Janosko worked on the ninth floor of New York's Memorial Sloan Kettering hospital, a place she describes as the happiest sad place she knows. The pediatric unit is filled with colorful artwork and laughter, but also the beeping of machines and the cries of children undergoing treatment. It's a place where hope and despair coexist.
When Izzy was diagnosed, Janosko knew the grim reality. DIPG is almost universally fatal, with a median survival of just 11 months. The tumor arises in the brainstem, making surgery nearly impossible, and the standard treatment of radiation and chemotherapy is ultimately ineffective. Janosko's only hope was to find a clinical trial that might offer Izzy a chance at a few more months or years of life, or perhaps even a glimpse of a cure.
But the Trump administration's dismantling of federal agencies, including drastic cuts to the National Institutes of Health (NIH), has had a devastating impact on cancer research. Budgets have been slashed, grants canceled or delayed, and clinical trials—the final hope for many children with terminal illnesses—have been suspended or closed. This has left families like Janosko's in a desperate search for options, as they watch their children's lives hang in the balance.
The paradox is striking. While Trump vowed to 'Make America Great Again,' his actions are undermining America's global leadership in the search for a cure for this devastating disease. Over the past 15 years, US medical centers have made groundbreaking discoveries in understanding child brain tumors, and American scientists have collaborated with colleagues worldwide to expand knowledge of the mutations that cause these tumors to grow. These advances have led to new treatments targeting the cancers' weak spots at a cellular level, offering a glimmer of hope for children with DIPG.
However, the Trump administration's policies are creating a countercurrent against this progress. The closure of the Pediatric Brain Tumor Consortium (PBTC), a group that has led the search for a cure for 25 years, has brought many of the continent's most promising clinical trials to a halt. Families like Izzy's are left with dwindling options, as the experiments they had pinned their hopes on are now closed to new patients.
The impact of these decisions is felt not only by families but also by the dedicated researchers and healthcare professionals who have devoted their lives to finding a cure. Dr. Eugene Hwang, a pediatric neuro-oncologist, has spent the past 15 years caring for children with brain tumors. He approaches each new patient with the ambition to cure them or prolong their life, but the current climate of uncertainty and funding cuts is making this mission increasingly difficult.
The story of Janosko and Izzy is just one of many, as families across the country grapple with the consequences of these policy decisions. The Trump administration's actions have not only affected the lives of children with cancer but also the future of medical research and innovation. The question remains: will the administration's priorities shift to support the search for a cure, or will children like Izzy continue to face an uncertain future?
